Published in Cell on June 30, 2006
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell (2006) 12.72
Identification of cells initiating human melanomas. Nature (2008) 8.28
Molecular basis of metastasis. N Engl J Med (2008) 8.19
TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell (2008) 7.60
HEF1-dependent Aurora A activation induces disassembly of the primary cilium. Cell (2007) 6.50
The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol (2007) 6.16
Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature (2007) 5.65
MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell (2009) 4.47
Translating insights from the cancer genome into clinical practice. Nature (2008) 4.37
Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell (2009) 3.85
Making sense of cancer genomic data. Genes Dev (2011) 3.01
Integrin signalling adaptors: not only figurants in the cancer story. Nat Rev Cancer (2010) 2.94
Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev (2006) 2.87
Unravelling the complexity of metastasis - molecular understanding and targeted therapies. Nat Rev Cancer (2011) 2.64
Melanoma: from mutations to medicine. Genes Dev (2012) 2.59
Tissue-specific and reversible RNA interference in transgenic mice. Nat Genet (2007) 2.54
Emerging patterns of somatic mutations in cancer. Nat Rev Genet (2013) 2.50
A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med (2008) 2.31
Nuclear factor I/B is an oncogene in small cell lung cancer. Genes Dev (2011) 2.29
Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma. PLoS Med (2008) 2.06
Proinvasion metastasis drivers in early-stage melanoma are oncogenes. Cancer Cell (2011) 1.99
Integrative genome comparison of primary and metastatic melanomas. PLoS One (2010) 1.97
An oncogenic role for ETV1 in melanoma. Cancer Res (2010) 1.94
CAS proteins in normal and pathological cell growth control. Cell Mol Life Sci (2009) 1.84
Losing balance: the origin and impact of aneuploidy in cancer. EMBO Rep (2012) 1.81
Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell (2012) 1.75
BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A (2013) 1.72
Cancer stem cells and human malignant melanoma. Pigment Cell Melanoma Res (2008) 1.65
Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination. Cancer Res (2009) 1.63
Melanoma MicroRNA signature predicts post-recurrence survival. Clin Cancer Res (2010) 1.59
Cell cycle-dependent ciliogenesis and cancer. Cancer Res (2008) 1.54
NEDD9 promotes oncogenic signaling in mammary tumor development. Cancer Res (2009) 1.53
A new central scaffold for metastasis: parsing HEF1/Cas-L/NEDD9. Cancer Res (2007) 1.48
NRG1 / ERBB3 signaling in melanocyte development and melanoma: inhibition of differentiation and promotion of proliferation. Pigment Cell Melanoma Res (2009) 1.45
Molecular basis for HEF1/NEDD9/Cas-L action as a multifunctional co-ordinator of invasion, apoptosis and cell cycle. Cell Biochem Biophys (2007) 1.45
Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma. Breast Cancer Res (2008) 1.38
Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. Oncogene (2010) 1.36
Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice. J Clin Invest (2010) 1.35
From cancer genomes to oncogenic drivers, tumour dependencies and therapeutic targets. Nat Rev Cancer (2012) 1.32
New roles of carboxypeptidase E in endocrine and neural function and cancer. Endocr Rev (2012) 1.23
The transcription factor Pax5 regulates its target genes by recruiting chromatin-modifying proteins in committed B cells. EMBO J (2011) 1.22
Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion. Oncogene (2013) 1.21
Regulation of invasive behavior by vascular endothelial growth factor is HEF1-dependent. Oncogene (2010) 1.19
NEDD9 is a positive regulator of epithelial-mesenchymal transition and promotes invasion in aggressive breast cancer. PLoS One (2011) 1.19
Genetically engineered mouse models in cancer research. Adv Cancer Res (2010) 1.18
Human melanoma metastasis in NSG mice correlates with clinical outcome in patients. Sci Transl Med (2012) 1.18
Pathways and therapeutic targets in melanoma. Oncotarget (2014) 1.17
NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma. Oncotarget (2012) 1.15
Gene signature of the metastatic potential of cutaneous melanoma: too much for too little? Clin Exp Metastasis (2010) 1.11
HEF1, a novel target of Wnt signaling, promotes colonic cell migration and cancer progression. Oncogene (2011) 1.10
Modulation of extracellular matrix/adhesion molecule expression by BRG1 is associated with increased melanoma invasiveness. Mol Cancer (2010) 1.10
Interdependence of cell attachment and cell cycle signaling. Curr Opin Cell Biol (2006) 1.08
A novel Cas family member, HEPL, regulates FAK and cell spreading. Mol Biol Cell (2008) 1.07
miR-145 functions as tumor suppressor and targets two oncogenes, ANGPT2 and NEDD9, in renal cell carcinoma. J Cancer Res Clin Oncol (2014) 1.07
A mouse stromal response to tumor invasion predicts prostate and breast cancer patient survival. PLoS One (2006) 1.07
Somatic structural rearrangements in genetically engineered mouse mammary tumors. Genome Biol (2010) 1.06
NEDD9 and BCAR1 negatively regulate E-cadherin membrane localization, and promote E-cadherin degradation. PLoS One (2011) 1.06
ZNF-mediated resistance to imatinib mesylate in gastrointestinal stromal tumor. PLoS One (2013) 1.06
Human enhancer of filamentation 1 Is a mediator of hypoxia-inducible factor-1alpha-mediated migration in colorectal carcinoma cells. Cancer Res (2010) 1.04
Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentials. World J Gastroenterol (2014) 1.04
Novel candidate cancer genes identified by a large-scale cross-species comparative oncogenomics approach. Cancer Res (2010) 1.03
Decoding melanoma metastasis. Cancers (Basel) (2010) 1.02
An N-terminal truncated carboxypeptidase E splice isoform induces tumor growth and is a biomarker for predicting future metastasis in human cancers. J Clin Invest (2011) 1.02
The Challenge of Cancer Genomics in Rare Nervous System Neoplasms: Malignant Peripheral Nerve Sheath Tumors as a Paradigm for Cross-Species Comparative Oncogenomics. Am J Pathol (2015) 0.99
Genetics and genomics of melanoma. Expert Rev Dermatol (2009) 0.98
A tumor suppressor function for the lipid phosphatase INPP4B in melanocytic neoplasms. J Invest Dermatol (2013) 0.97
NSP-Cas protein structures reveal a promiscuous interaction module in cell signaling. Nat Struct Mol Biol (2011) 0.97
Melanoma: Stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications. J Carcinog (2010) 0.97
Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers. BMC Cancer (2010) 0.97
Involvement of actinin-4 in the recruitment of JRAB/MICAL-L2 to cell-cell junctions and the formation of functional tight junctions. Mol Cell Biol (2008) 0.97
Multiple actions of lysophosphatidic acid on fibroblasts revealed by transcriptional profiling. BMC Genomics (2008) 0.97
G-protein-coupled receptors and melanoma. Pigment Cell Melanoma Res (2008) 0.97
A mouse plasma peptide atlas as a resource for disease proteomics. Genome Biol (2008) 0.96
Enhanced genetic instability and dasatinib sensitivity in mammary tumor cells lacking NEDD9. Cancer Res (2010) 0.96
HOXA1 drives melanoma tumor growth and metastasis and elicits an invasion gene expression signature that prognosticates clinical outcome. Oncogene (2013) 0.96
Identification of genes with allelic imbalance on 6p associated with nasopharyngeal carcinoma in southern Chinese. PLoS One (2011) 0.94
Aurora A is differentially expressed in gliomas, is associated with patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas. Cell Cycle (2012) 0.94
NEDD9 depletion destabilizes Aurora A kinase and heightens the efficacy of Aurora A inhibitors: implications for treatment of metastatic solid tumors. Cancer Res (2013) 0.93
The nerve growth factor receptor CD271 is crucial to maintain tumorigenicity and stem-like properties of melanoma cells. PLoS One (2014) 0.92
LKB1 represses focal adhesion kinase (FAK) signaling via a FAK-LKB1 complex to regulate FAK site maturation and directional persistence. J Biol Chem (2013) 0.92
Prognostic factors related with survival in patients with pancreatic adenocarcinoma. World J Gastroenterol (2014) 0.92
The overexpression of scaffolding protein NEDD9 promotes migration and invasion in cervical cancer via tyrosine phosphorylated FAK and SRC. PLoS One (2013) 0.92
Long non-coding RNAs in cancer and development: where do we go from here? Int J Mol Sci (2015) 0.92
The CRTC1-NEDD9 signaling axis mediates lung cancer progression caused by LKB1 loss. Cancer Res (2012) 0.91
Integrative oncogenomic approaches for accelerated cancer-gene discovery. Curr Opin Oncol (2008) 0.91
Differential gene expression triggered by highly cytotoxic alpha-emitter-immunoconjugates in gastric cancer cells. Invest New Drugs (2009) 0.91
Rb inactivation accelerates neoplastic growth and substitutes for recurrent amplification of cIAP1, cIAP2 and Yap1 in sporadic mammary carcinoma associated with p53 deficiency. Oncogene (2010) 0.90
Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis. Am J Pathol (2013) 0.89
Distinct patterns of DNA copy number alterations associate with BRAF mutations in melanomas and melanoma-derived cell lines. Genes Chromosomes Cancer (2009) 0.89
Prioritization of candidate cancer genes--an aid to oncogenomic studies. Nucleic Acids Res (2008) 0.88
Progression of cutaneous melanoma: implications for treatment. Clin Exp Metastasis (2012) 0.87
Metastasis in an orthotopic murine model of melanoma is independent of RAS/RAF mutation. Melanoma Res (2010) 0.87
Applications of genomics in melanoma oncogene discovery. Hematol Oncol Clin North Am (2009) 0.87
Cytoskeleton alterations in melanoma: aberrant expression of cortactin, an actin-binding adapter protein, correlates with melanocytic tumor progression. Mod Pathol (2009) 0.87
Cross-species oncogenomics in cancer gene identification. Cell (2006) 0.87
NEDD9 depletion leads to MMP14 inactivation by TIMP2 and prevents invasion and metastasis. Mol Cancer Res (2013) 0.86
A remarkable new target gene for the dioxin receptor: The Vav3 proto-oncogene links AhR to adhesion and migration. Cell Adh Migr (2010) 0.85
NSP-CAS Protein Complexes: Emerging Signaling Modules in Cancer. Genes Cancer (2012) 0.84
Comparative oncogenomic analysis of copy number alterations in human and zebrafish tumors enables cancer driver discovery. PLoS Genet (2013) 0.84
Progress in understanding melanoma propagation. Mol Oncol (2010) 0.84
A microRNA polycistron as a potential human oncogene. Nature (2005) 40.21
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2009) 24.27
International network of cancer genome projects. Nature (2010) 20.35
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell (2006) 18.81
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature (2007) 16.95
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell (2006) 12.72
A landscape of driver mutations in melanoma. Cell (2012) 12.61
WHO-EORTC classification for cutaneous lymphomas. Blood (2005) 12.14
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science (2007) 10.60
Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 9.41
FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell (2007) 8.94
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature (2004) 8.76
Highly recurrent TERT promoter mutations in human melanoma. Science (2013) 8.40
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
Identification of cells initiating human melanomas. Nature (2008) 8.28
Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA (2003) 8.07
Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science (2003) 7.86
Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77
Pten dose dictates cancer progression in the prostate. PLoS Biol (2003) 7.62
Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell (2007) 7.60
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell (2012) 7.36
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet (2009) 7.26
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet (2011) 6.89
A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol (2004) 6.61
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell (2009) 6.55
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med (2007) 6.55
High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci U S A (2005) 6.52
Telomere dysfunction induces metabolic and mitochondrial compromise. Nature (2011) 6.36
CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature (2008) 6.24
Glioblastoma stem-like cells give rise to tumour endothelium. Nature (2010) 6.18
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med (2005) 6.04
Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods (2006) 5.96
Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A (2006) 5.90
An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet (2003) 5.82
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature (2007) 5.65
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63
Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell (2007) 5.62
A genetic screen for candidate tumor suppressors identifies REST. Cell (2005) 5.61
High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov (2011) 5.30
NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell (2007) 5.20
Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol (2006) 5.10
The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med (2004) 5.01
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell (2006) 5.01
p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature (2008) 5.00
A public genome-scale lentiviral expression library of human ORFs. Nat Methods (2011) 4.98
Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature (2005) 4.97
Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood (2010) 4.96
miR-19 is a key oncogenic component of mir-17-92. Genes Dev (2009) 4.95
Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res (2006) 4.80
Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell (2007) 4.75
Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell (2008) 4.71
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71
SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature (2011) 4.57
Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell (2006) 4.52
Regulation of in situ to invasive breast carcinoma transition. Cancer Cell (2008) 4.46
The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. J Clin Invest (2011) 4.41
Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature (2004) 4.41
Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37
Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice. Nature (2010) 4.36